Lycia Therapeutics CEO holds options on 471,252 shares

The report lists four direct option positions with distinct exercise prices and expiration dates, plus 415,255 common shares held by a family trust.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. (LYCA) lists President and CEO, director, and ten percent owner Aetna Wun Trombley’s direct options covering 471,252 shares at $1.63, fully vested, expiring October 19, 2031; 665,380 at $2.44, expiring June 27, 2034; 55,448 at $2.35, expiring February 9, 2036; and 443,586 at $3.70, expiring August 10, 2036. The latter three awards vest monthly, subject to her providing service on each vesting date. The Trombley Family Trust, of which she and her spouse are trustees, holds 415,255 common shares.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Trombley Aetna Wun

Role President and CEO

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F2	--	--	--
holding	Stock Option (Right to Buy) F3	--	--	--
holding	Stock Option (Right to Buy) F4	--	--	--
holding	Stock Option (Right to Buy) F5	--	--	--
holding	Common Stock F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,635,666 contracts (Direct); Common Stock — 415,255 shares (Indirect, By Trust)

Footnotes (5)

1. F1. These securities are held by the Trombley Family Trust of which the Reporting Person and her spouse are trustees.
2. F2. The options are fully vested.
3. F3. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. F4. The options vested as to 1/48 of the total award on February 1, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5. F5. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Shares underlying options; exercise price: 471,252 shares; $1.63 per share Shares underlying options; exercise price: 665,380 shares; $2.44 per share Shares underlying options; exercise price: 55,448 shares; $2.35 per share +2 more

5 metrics

Shares underlying options; exercise price 471,252 shares; $1.63 per share Fully vested; expires October 19, 2031

Shares underlying options; exercise price 665,380 shares; $2.44 per share Vests monthly subject to service; expires June 27, 2034

Shares underlying options; exercise price 55,448 shares; $2.35 per share Vests monthly subject to service; expires February 9, 2036

Shares underlying options; exercise price 443,586 shares; $3.70 per share Vests monthly subject to service; expires August 10, 2036

Common shares held by trust 415,255 shares Held by the Trombley Family Trust, of which Aetna Wun Trombley and her spouse are trustees

Key Terms

Stock Option (Right to Buy), fully vested, vest monthly thereafter

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

fully vested financial

"The options are fully vested."

vest monthly thereafter financial

"an additional 1/48 of the award will vest monthly thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options does Aetna Wun Trombley hold in LYCA?

Aetna Wun Trombley’s reported direct options cover 471,252 shares at $1.63, 665,380 at $2.44, 55,448 at $2.35, and 443,586 at $3.70. The first option is fully vested; the other three awards vest monthly, subject to her providing service on each vesting date.

How many LYCA shares are held by the Trombley Family Trust?

The Trombley Family Trust holds 415,255 common shares. Aetna Wun Trombley and her spouse are trustees of the trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trombley Aetna Wun

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	415,255	I	By Trust(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	10/19/2031	Common Stock	471,252	$1.63	D
Stock Option (Right to Buy)	(3)	06/27/2034	Common Stock	665,380	$2.44	D
Stock Option (Right to Buy)	(4)	02/09/2036	Common Stock	55,448	$2.35	D
Stock Option (Right to Buy)	(5)	08/10/2036	Common Stock	443,586	$3.7	D

Explanation of Responses:

1. These securities are held by the Trombley Family Trust of which the Reporting Person and her spouse are trustees.

2. The options are fully vested.

3. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

4. The options vested as to 1/48 of the total award on February 1, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

5. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)